Koletar, Susan

Susan L. Koletar, MD, FACP
Professor, Internal Medicine
Fellowship Program Director

N1135 Doan Hall
410 W. 10th Avenue
Columbus, Ohio 43210
(614) 293-8732
koletar.1@osu.edu

Dr. Koletar joined the faculty in 1988. She has been the Fellowship Program Training Director since 1993 and the Principal Investigator of the National Institutes of Health-sponsored AIDS Clinical Trials Unit at OSU since January 2002. Her commitment to education has been recognized by a number of teaching awards, including the College of Medicine’s Professor of the Year in 1995 and the American College of Physicians/American Society of Internal Medicine Master Teacher Award in 2002.

Special Interests
Dr. Koletar's clinical interests are infections in immunocompromised hosts, especially HIV-infected and transplant recipients. Her research interests are the diagnosis, treatment, and prevention of opportunistic and metabolic complications associated with HIV infection and its related therapies. She is currently working on a number of AIDS Clinical Trials Group protocols including a longitudinal study of metabolic, cardiovascular, and neurologic complications in HIV-infected patients who have had significant increases in CD4 counts in response to potent antiretroviral therapy.

Education
M.D., West Virginia University, 1983
Internship: Charleston Area Medical Center, 1986
Residency:Charleston Area Medical Center, 1986
Subspecialty Training: The Ohio State University, 1988

Select Publications
Koletar SL, Heald AE, Finkelstein D, Hafner R, Currier JS, McCutchan JA, Vallee M, Torriani FJ, Powderly WG, Fass RJ, and Murphy RL, for the ACTG 888 Study Team. A Prospective Study of Discontinuing Primary and Secondary Pneumocystis carinii Prophylaxis after CD4+ Counts Increase to >200 cells/mm3. AIDS 15:1509-15, 2001.

Neidig JL, Koletar SL, Safety reporting in clinical trials.  JAMA 285:2077,2001

von Reyn CF , Williams PL, Lederman HM, McCutchan JA, Koletar SL, Murphy RL, Cohn SE, Evans T, Heald AE , Colquhoun D, Bassily EL, Currier JS. Skin test reactivity and cellular immune responses to Mycobacterium avium sensitin in AIDS patients at risk for disseminated M. avium infection. Clinical and Diagnostic Laboratory Immunology 8(6):1277-78, 2001.

Aberg JA, Chin-Hong PV, McCutchan JA, Koletar SL, Currier JS for the AIDS Clinical Trial Group 362 and 393 Study Teams. Localized Osteomyelitis Due to Mycobacterium avium Complex in Patients with Human Immunodeficiency Virus Receiving Highly Active Antiretroviral Therapy. Clin Inf Dis 35:e8–13, 2002.

de Boer AW, Markowitz N, Lane HC, Saravolatz LD, Koletar SL, Donabedian H, Yoshizawa C, Duliege A-M, Fyfe G, Mitsuyasu RT. A Randomized Controlled Trial Evaluating the Efficacy and Safety of Intermittent 3, 4, and 5 Day Cycles of Intravenous Recombinant Human Interleukin-2 for s Combined With Antiretroviral Therapy (ART) vs ART Alone in HIV-seropositive Patients With 100-300 CD4+ T-cells. Clinical Immunology, 106(3):188-96, 2003.

Lederman HM, Williams PL, Wu JW, Evans TG, Cohn SE, McCutchan JA, Koletar SL, Hafner R, Connick E, Valentine FT, McElrath MJ, Roberts Jr. NJ, and Currier JS for the AIDS Clinical Trials Group 889 Study Team.  Incomplete Immune Reconstitution After Institution of Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus-Infected Patients with Severe CD4 Depletion. Journ Inf Dis 2003; 188:1794-803.

Wohl DA, Pilcher CD, Revuelta M, McComsey G, Yang Y, Evans S, Zackin R,  Alston B, Welch S, Basar M, Kashuba A, Kondo P, Martinez A, Giardini J, Quinn J, Littles M, Wingfield H and Koletar SL for the Adult AIDS Clinical Trials Group A5129 Team.  Absence of Sustained Hyperlactatemia in HIV-Infected Patients with Risk Factors for Mitochondrial Toxicity. J Acquir Immune Defic Syndr 2004; 35(3): 274-278.

Goldman M, Zackin R, Fichtenbaum CJ, Skiest DJ, Koletar SL, Hafner R, Wheat LJ, Nyangweso PM, Yiannoutsos CT, Schnizlein-Bick CT, Owens S, Aberg JA, and the AIDS Clinical Trials Group A5038 Study Group. Safety of discontinuation of maintenance therapy for disseminated histoplasmosis following immunologic response to antiretroviral therapy. AIDS Clinical Trials Group Study A5038. Clin Inf Dis 2004;38:1485-9.

Koletar SL, Williams P., Wu J, McCutchan JA, Cohn SE , Murphy RL , Lederman HM, Currier JS for the ACTG 362 Study Team. Long-Term Follow-up of HIV-Infected Individuals Who Have Significant CD4 Increases with Antiretroviral Therapy. Clin Inf Dis 2004;39:1500-06.

Koletar SL, Williams P., Wu J, McCutchan JA, Cohn SE , Murphy RL , Lederman HM, Currier JS .  Reply to Philips – Letter to the Editor. Clin Infect Dis. 2005 May 1;40(9):1380-1381.

MacGregor RR, Hafner R, Wu JW, Murphy RL, Perlman DC, Bermudez LE, Inderlied CB, Picker LJ, Wallis RS, Andersen JW, Mahon LF, Koletar SL, Peterson DM; ACTG Protocol 341 Team. Clinical, microbiological, and immunological characteristics in HIV-infected subjects at risk for disseminated Mycobacterium avium complex disease: an AACTG study. AIDS Res Hum Retroviruses. 2005 Aug;21(8):689-95.

Joy S, Poi M, Hughes L, Brady M, Koletar SL, Para MF, Fan-Havard P. Third Trimester Maternal Toxicity with Nevirapine Use in Pregnancy. Obstetrics & Gynecology 2005;106(5, Part 1):1032-1038.

Links
Aids Clinical Trials Unit